Metastasis Archives

New Use of an Old Drug Could Address Cancer Metastasis

By

January 24, 2017

CDK 4/6 inhibitors, currently approved for the treatment of estrogen-positive breast cancer, were found to inhibit metastasis in triple-negative breast

Lung Cancer

Atezolizumab Granted FDA Approval for Specific Cases of NSCLC

By

Joyce Pagan

October 19, 2016

Atezolizumab (Tecentriq) is approved by the FDA for the treatment of metastatic NSCLC in specific cases or tumors with EGFR or ALK gene mutations.

Head and Neck Cancer

Outcomes in Patients With Brain Metastasis from Esophageal Carcinoma

By

Nishi Kothari, Eric Mellon, Sarah E. Hoffe, Jessica Frakes, Ravi Shridhar, Jose Pimiento, Ken Meredith, Nam D. Tran, Nadia Saeed, Khaldoun Almhanna

September 9, 2016

[Journal of Gastrointestinal Oncology] This research examines factors associated with survival in patients with brain metastasis from esophageal cancer.

General Oncology

Understanding a Molecular Switch Modulating Tumor Metastasis and Chemotherapy Resistance

By

Kathy Boltz, PhD

July 21, 2016

Dab2 is an endocytic adaptor and tumor suppressor whose expression occurs during the epithelial-mesenchymal transition, which is mediated by TGF-beta. This study sought to understand how Dab2 regulates apoptosis.

Pancreatic Cancer

Metastatic Ability May Precede Tumor Formation in Pancreatic Cancer

By

Megan Garlapow, PhD

June 15, 2016

Metastatic capabilities of pancreatic cancer might arise before tumors even form. Metastasis and advanced stage of disease at diagnosis are attributed to low survival rates for pancreatic cancer.

ASCO 2016 Annual Meeting

Dabrafenib Plus Trametinib Continue to Show Survival Benefit in BRAF-mutant Metastatic Melanoma

By

Debra Hughes, MS

June 7, 2016

The longest overall survival follow-up among randomized phase 3 trials evaluating BRAF and MEK inhibitors in patients with BRAF-mutant metastatic melanoma to date has shown the best 3-year outcome with dabrafenib plus trametinib to be in patients with normal LDH and fewer than 3 disease sites, according to a presentation at the ASCO 2016 Annual Meeting.

ASCO 2016 Annual Meeting

Palbociclib Plus Fulvestrant Provides Significant Benefit in Hormone Receptor-Positive Metastatic Breast Cancer

By

Debra Hughes, MS

June 4, 2016

ESR1 mutations detected in plasma circulating tumor DNA were identified in a high percentage of patients with hormone receptor-positive metastatic breast cancer, confirming an important role in endocrine resistance, according to an analysis of data from the phase 3 PALOMA-3 reported at the 2016 ASCO Annual Meeting.

ASCO 2016 Annual Meeting

ESR1 Mutations Predict Worse Outcome in HR-positive Metastatic Breast Cancer Treated with Aromatase Inhibitors

By

Debra Hughes, MS

June 4, 2016

The presence of circulating ESR1 somatic mutations at disease progression in patients with HR-positive metastatic breast cancer treated with first-line AIs represent a strong and independent poor prognostic value for overall survival but no predictive value, a study presented at the 2016 ASCO Annual Meeting has found.